Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dinoprostone
Drug ID BADD_D00684
Description Dinoprostone is a naturally occurring prostaglandin E2 (PGE2). It has important effects in labour. It also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts. As a prescription drug it is used as a vaginal suppository, to prepare the cervix for labour and to induce labour.
Indications and Usage For the termination of pregnancy during the second trimester (from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period), as well as for evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period. Also used in the management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole). Other indications include improving the cervical inducibility (cervical "ripening") in pregnant women at or near term with a medical or obstetrical need for labor induction, and the management of postpartum hemorrhage.
Marketing Status Prescription
ATC Code G02AD02
DrugBank ID DB00917
KEGG ID D00079
MeSH ID D015232
PubChem ID 5280360
TTD Drug ID D06FEA
NDC Product Code 45542-1153; 68245-0015; 0009-3359; 40016-012; 0009-0058; 12079-0485; 82231-104; 55566-2800
Synonyms Dinoprostone | PGE2 alpha | alpha, PGE2 | Prostaglandin E2alpha | E2alpha, Prostaglandin | Prostaglandin E2 | E2, Prostaglandin | Prostaglandin E2 alpha | E2 alpha, Prostaglandin | alpha, Prostaglandin E2 | PGE2 | PGE2alpha | Prepidil Gel | Gel, Prepidil | Prostenon
Chemical Information
Molecular Formula C20H32O5
CAS Registry Number 363-24-6
SMILES CCCCCC(C=CC1C(CC(=O)C1CC=CCCCC(=O)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
MiosisVasopressin V1a receptorP37288T792323460310; 6385626; 3485638; 716972
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pregnancy18.08.02.004--Not Available
Premature baby18.04.02.0010.000256%Not Available
Premature rupture of membranes18.07.01.003--Not Available
Premature separation of placenta24.07.03.019; 18.02.01.0040.001364%Not Available
Presyncope02.01.02.007; 24.06.02.010; 17.02.05.009--
Pyrexia08.05.02.0030.000341%
Rash23.03.13.001--Not Available
Seizure17.12.03.0010.000170%
Sepsis neonatal18.04.12.003; 11.01.11.0070.000341%Not Available
Shock24.06.02.002--Not Available
Skin discolouration23.03.03.005--Not Available
Stillbirth18.01.02.002; 08.04.01.006--Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.000170%
Tachycardia02.03.02.0070.000256%Not Available
Tachycardia foetal18.03.02.005; 02.03.02.0170.000256%Not Available
Tension19.06.02.005--Not Available
Tremor17.01.06.0020.000256%
Urinary retention20.02.02.011--
Uterine haemorrhage24.07.03.004; 21.07.01.0050.000067%
Uterine hypertonus18.07.02.003; 21.07.03.0040.000597%Not Available
Uterine rupture21.07.01.009; 18.02.02.001; 12.01.15.0010.001023%Not Available
Vaginal haemorrhage21.08.01.001; 24.07.03.0050.000170%
Vaginal infection21.14.02.002; 11.01.10.002--
Vaginal inflammation21.14.02.001--
Vertigo17.02.12.002; 04.04.01.0030.000170%
Vision blurred06.02.06.007; 17.17.01.010--
Vomiting07.01.07.003--
Vulvitis21.14.02.006; 11.01.10.007--
Vulvovaginal discomfort21.08.02.0050.000426%Not Available
Vulvovaginal dryness21.08.02.0030.000256%
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages